Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income from Continuing Operations (2023 - 2025)

CG Oncology (CGON) has disclosed Income from Continuing Operations for 3 consecutive years, with 41256000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 29.72% year-over-year to 41256000.0, compared with a TTM value of 160843000.0 through Dec 2025, down 82.69%, and an annual FY2025 reading of 160843000.0, down 82.69% over the prior year.
  • Income from Continuing Operations was 41256000.0 for Q4 2025 at CG Oncology, up from 43708000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8675000.0 in Q1 2023 and bottomed at 43708000.0 in Q3 2025.
  • Average Income from Continuing Operations over 3 years is 24785833.33, with a median of 19656500.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 29.72% in 2025, while the deepest fall reached 119.05% in 2025.
  • Year by year, Income from Continuing Operations stood at 16551000.0 in 2023, then crashed by 92.16% to 31804000.0 in 2024, then decreased by 29.72% to 41256000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CGON at 41256000.0 in Q4 2025, 43708000.0 in Q3 2025, and 41422000.0 in Q2 2025.